VANCOUVER — Angiotech Pharmaceuticals Inc. (TSX:ANP) is seeking to raise up to US$250 million over next 25 months, the company said Thursday. The drug and medical device company filed a prospectus Thursday with Canadian and U.S. regulatory authorities that would allow Angiotech to issue shares, debt securities, warrants or units. Vancouver-based Angiotech said it intends to use the proceeds for general corporate purposes, including research and development programs, capital expenditures, working capital and repayment or refinancing of debt. Shares in Angiotech, which has 85.1 million shares outstanding, closed at $1.98 on the Toronto Stock Exchange on Thursday.
